Safety, Tolerability Study of SG2000 in the Treatment of Advanced Chronic Lymphocytic Leukemia and Acute Myeloid Leukemia
NCT02034227
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
TERMINATED
Status
6
Enrollment
INDUSTRY
Sponsor class
Conditions
Acute Myeloid Leukemia
Chronic Lymphocytic Leukemia
Interventions
DRUG:
SG2000
Sponsor
Spirogen